Nirsevimab’s Protection Extended Beyond the First RSV Season in Galicia
Universal infant nirsevimab prophylaxis in Galicia was linked to a large drop in respiratory syncytial virus-related lower respiratory tract infection hospitalizations during the first season, and the protection did not disappear when children moved into the second season. The first-season reduction was 85.9% (95% CI 80.2-90.0), and the second-season reduction still measured 55.3% (95% CI 22.5-74.3). For a passive immunization strategy that does not create sterilizing immunity, that pattern is clinically arresting.
The finding matters because monoclonal antibody prophylaxis has usually been framed as short-lived protection against the vulnerable infant months when RSV hospitalizations peak. Here, severe outcomes remained lower even after the original season had passed. The second-season signal did not appear to come with a tradeoff in the form of enhanced disease or a shift toward worse illness in older children, which is reassuring in a field where concerns about altered immune responses have long shaped practice.
A Second-Season Signal Without Enhanced Disease
The central observation is straightforward: children protected in season one did not simply rebound with a heavier burden of severe RSV disease in season two. Recurrent severe outcomes were also reduced, and no evidence emerged for enhanced disease after prophylaxis. In bedside terms, that means the program did not merely defer the problem into a later, more dangerous window.
This is especially important because the biology of passive prophylaxis differs from vaccination. Nirsevimab supplies circulating neutralizing activity, but it does not train the immune system to generate durable sterilizing protection on its own. Any benefit that extends beyond the dosing window therefore demands a mechanism other than classical long-term immunity. The Galicia findings invite a more nuanced view of how preventing early severe RSV may alter the course of later disease burden.
One plausible explanation is simple but clinically meaningful: infants who avoid a severe RSV hospitalization in their first season may also avoid becoming the children most likely to reappear in the second. If severe first-season disease marks an underlying susceptibility endotype, then early prophylaxis could preferentially protect those most likely to return with serious illness later. In that sense, the observed second-season benefit may reflect selective preservation of the highest-risk subgroup rather than a direct carryover of antibody effect alone.
Why the Benefit Could Persist After Passive Protection Fades
Several biologic mechanisms can fit the pattern, and none are mutually exclusive. Preserving lung architecture during an important developmental period could matter more than the acute infection itself. Infant lungs are still growing, and a severe RSV episode during that window can plausibly leave a child with less resilient airways or altered pulmonary reserve. Preventing that injury in season one may reduce downstream vulnerability even after the monoclonal antibody is no longer circulating at protective levels.
A second mechanism sits in the immune system. Severe viral lower respiratory infection can drive inflammatory and epigenetic reprogramming, particularly in a developing host. If RSV hospitalizations are prevented early, the child may avoid a cascade of immune remodeling that would otherwise amplify later severity. Controlled antigen exposure may also play a role, allowing some immune engagement without the intensity of full-blown lower respiratory tract disease.
A modest pharmacokinetic tail offers an additional, more prosaic explanation. Even if protective concentrations wane over time, residual activity may extend the period of partial protection beyond the season in which prophylaxis was administered. The article does not claim that this tail alone explains the second-season effect, and it should not be overinterpreted. Still, in a real-world program, even a small extension of biologic effect can alter hospitalization patterns when circulation of a seasonal virus is uneven.
Implications for Sequencing Passive and Active Prevention
The absence of enhanced disease has immediate programmatic value. It supports the current sequencing logic in which passive prophylaxis can reduce early infant morbidity without creating a detectable rebound in severity later. That reassurance is central to adoption decisions, parent counseling, and the design of future prevention programs that may combine monoclonal antibodies with active immunization strategies.
The second-season observations also sharpen the question of who benefits most from prophylaxis. If the sustained reduction is driven in part by preventing severe disease in a subgroup with higher intrinsic susceptibility, then risk stratification could become more refined over time. If, instead, the effect depends mainly on lung-sparing during a critical developmental interval, then the timing of protection may be as important as the baseline risk profile itself.
Both interpretations carry practical weight. Pediatric services do not just need to know whether prophylaxis works; they need to know why it works, how long the benefit lasts, and which children are most likely to lose ground without it. Galicia provides a signal that the consequences of first-season protection may extend further than initially assumed.
Why Caution Still Applies to This Cohort
The second-season finding has not yet been replicated across other cohorts, so it should be read as hypothesis-generating rather than definitive proof of durable programmatic effect. The size of the confidence interval for the second-season estimate is wide, and that alone signals uncertainty around the exact magnitude of benefit. A single regional experience cannot settle the question of generalizability, especially when RSV circulation, healthcare access, hospitalization thresholds, and prophylaxis uptake can differ across settings.
Still, the study does more than add another effectiveness estimate. It exposes a mechanistic gap in current thinking about passive RSV prevention. If a child receives nirsevimab in infancy and later shows lower hospitalization risk without any sign of disease enhancement, the explanation cannot rest on sterilizing immunity. The more likely answer lies in altered disease trajectory: fewer severe early infections, less lung injury, less immune reprogramming, and a smaller pool of children primed for repeat hospitalization.
Those hypotheses are testable. Future programme-embedded research can track whether protection clusters in children with specific vulnerability profiles, whether early prophylaxis changes later wheezing or respiratory morbidity, and whether pharmacokinetic persistence contributes more than expected. For now, the Galicia data offer a clinically useful signal: preventing severe RSV in infancy may influence not only the current season, but the one that follows.